AwesomeCapital
Search This Blog
Monday, November 25, 2019
BMO Starts Rapt Therapeutics (RAPT) at Outperform
‘Altering Immune Response Through CCR4’: analyst Do Kim.
Target $35
https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+BMO+Capital+Starts+Rapt+Therapeutics+%28RAPT%29+at+Outperform%2C+Altering+Immune+Response+Through+CCR4/16173232.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.